% | $
Quotes you view appear here for quick access.


  • pharmaherooe pharmaherooe Nov 22, 2011 10:14 AM Flag

    (ALXA) APPROVAL decision on Dec 12th //TOP PICK


    FDA approval will push this stock to $5++ easily because ADASUVE has HUGE sales potential .

    Get in NOW and make some quick profits then sell before the Meeting IF you are a weaky or hold trough the meeting if you are a stronger shareholder ...

    RUNUP will bring this back near $2 .....GL

    Alexza Pharma (ALXA)

    Market Cap: 76.4 M
    Cash: 28.3 M
    Price: 1.07

    On October 24, 2011, Alexza announced that the FDA has scheduled a meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) for December 12, 2011, at which the ADASUVE NDA will be discussed.

    In August 2011, the U.S. Food and Drug Administration (FDA) accepted Alexza's resubmission of the Adasuve™ (Staccato® Loxapine) New Drug Application (NDA) as a complete, class 2 response to the FDA's Complete Response Letter, and indicated a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

    On October 5, 2011, Alexza entered into a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A. (Grupo Ferrer) for the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.


    This topic is deleted.